From: Cognitive function in recovered COVID-19 Lebanese patients with schizophrenia
 | Frequency (%) |
---|---|
Patients diagnosed with COVID-19 | |
 Yes | 71 (74.7%) |
 No | 24 (25.3%) |
Severity of the COVID-19 infection | |
 Asymptomatic | 32 (45.1%) |
 Mild | 34 (47.9%) |
 Moderate | 0 (0.0%) |
 Severe | 5 (7.0%) |
Presence of post-COVID-19 symptoms | |
 Cough | 4 (5.7%) |
 Fever | 2 (2.9%) |
 Dyspnea | 14 (20.0%) |
 Chest pain | 9 (12.9%) |
 Diarrhea | 4 (5.7%) |
 Abdominal pain | 6 (8.6%) |
 Loss of taste | 5 (7.1%) |
 Loss of smell | 5 (7.1%) |
 Sore throat | 3 (4.3%) |
 Nausea | 8 (11.4%) |
 Vomiting | 3 (4.3%) |
 Headache | 9 (12.9%) |
 Myalgia | 7 (10.0%) |
 Arthralgia | 13 (18.6%) |
 Fatigue | 37 (52.9%) |
 Rash | 0 (0%) |
Number of post-COVID-19 symptoms | |
 0 | 26 (37.1%) |
 1 | 16 (22.9%) |
 2 | 12 (17.1%) |
  > 2 | 16 (22.9%) |
 | Mean ± SD |
Duration between the cognitive evaluation at baseline and post-COVID period cognitive assessment by month | 20.65 ± 1.47 |
Duration between the infection by the SARS-CoV-2 virus and post cognitive assessment by month | 6.62 ± 1.94 |